Literature DB >> 17693997

Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane.

J Ruys, J J De Laey, Y Vanderhaeghen, E H Van Aken.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693997     DOI: 10.1038/sj.eye.6702946

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  6 in total

1.  Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors:  Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

2.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 3.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

Review 4.  Anti-vascular endothelial growth factor indications in ocular disease.

Authors:  Stefan Cornel; Iliescu Daniela Adriana; Timaru Cristina Mihaela; Schmitzer Speranta; De Simone Algerino; Batras Mehdi; Hosseini-Ramhormozi Jalaladin
Journal:  Rom J Ophthalmol       Date:  2015 Oct-Dec

5.  Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

Authors:  Pukhraj Rishi; Daraius Shroff; Ekta Rishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-12       Impact factor: 3.117

6.  A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis.

Authors:  Dimitrios Karagiannis; Ilias Georgalas; Ioannis Ladas; Parikakis Eustratios; Panagiotis Mitropoulos
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.